Canada-based Highland Therapeutics has reported positive results from a Phase I study of a novel formulation of methylphenidate, HLD-200, to treat attention-deficit/hyperactivity disorder (ADHD).
Conducted in collaboration with the Harvard Clinical Research Institute (HCRI) and Massachusetts General Hospital (MGH), the study of HLD-200 was conducted on humans for the first time to examine its pharmacokinetic profile.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The study noted a longer absorption window for HLD-200, when compared with other methylphenidate products available in the market.
In the single-centre, single-dose, open-label trial, 12 patients were enrolled and administered with two methylphenidate HCl modified release and an immediate release methylphenidate HCl marketed formulations subsequent to a washout period between treatments.
The study highlights the class-leading low level of variability with respect to a critical parameter, the time to maximum concentration (Tmax), and a similar low coefficient of variation (CV%) to that of the HLD-100 Phase-1 study.
Senior study adviser and medical monitor, MGH paediatric psychopharmacology and adult ADHD clinical and research programmes chief Dr Joseph Biederman said, "The data suggest that Highland has developed a potential new treatment option for ADHD that could consistently deliver the medication so that the symptoms of ADHD can be controlled immediately upon wakening while also providing once-daily coverage."
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHighland chief executive officer David Lickrish said the data for both amphetamine and methylphenidate programmes suggest that the drug-delivery technology is a platform technology, applicable to other active ingredients in a range of therapeutic categories.
"The third-party market research we have conducted indicates substantial pent-up demand for Highland’s products, which could become first-line therapy in both the adult and pediatric/adolescent patient populations," Lickrish added.
